Funds with similar focus
|Beijing Fen Xin Investment Management||Beijing, Beijing, China|
|Chongqing Dongzheng Huaixin Guquan Touzi Jijin Hehuo Qiye (Youxian Hehuo)||China, Chongqing, Jiulongpo|
|Full Tilt Capital||California, San Diego, United States|
|Guangdong Hongmi Touzi Hehuo Qiye (Putong Hehuo)||China, Guangdong, Zhangshan|
|Huiming Touzi||China, Shanghai|
|Invest In Visions||-|
|Irelandia Investments||County Dublin, Dublin, Ireland|
|Maroon Bells Capital Partners||California, San Francisco, United States|
|MF Private Capital||Boston, Massachusetts, United States|
|Opium Ventures||China, Hong Kong, Hong Kong Island|
|PTEK Ventures||Atlanta, Georgia, United States|
|Ruian Real Estate Development Management||China, Shanghai|
|Shinhan Capital||Seoul, Seoul-t'ukpyolsi, South Korea|
|Societe Generale||France, Ile-de-France, Paris|
|SuRo Capital||California, San Francisco, United States|
|Yizheng Ziben||China, Guangdong, Tianjin|
|$25M||20 Aug 2021||New York, New York, United States|
|$79M||15 Aug 2021||South Oxfordshire, England, United Kingdom|
|01 Jan 2021||New York, New York, United States|
|20 Oct 2019||New York, United States|
|$26M||10 Oct 2019||New York, New York, United States|
|$30M||10 Dec 2018||Los Angeles, California, United States|
|01 Jul 2018||New York, United States|
|15 Jun 2018||New York, New York, United States|
|$5M||07 Jan 2018||San Francisco, California, United States|
– Beckley Psytech an Oxford, England-based private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines closed an $80m Series B financing.
– The round was led by Integrated with participation from Prime Movers Labs, Adage Capital Management, Palo Santo; Delphi VC; Leafy Tunnel; Negev Capital; and existing investor Bicycle Day Ventures.
– The company intends to use the funds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression, and expand its pipeline with new, unique and proprietary psychedelic compounds.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.